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Abstract 
Purpose: To investigate the impact of twice daily inhalation of 100 µg of salmeterol or 12 µg 
of formoterol in addition to a strength and power training programme over a 5-wk period on 
30-m sprint, strength, power, mood, stress, and skinfold thickness. 
Methods: In a randomized single-blind study, 23 male and 15 female nonasthmatic, 
recreationally active individuals were recruited (mean ± SD age 26.3 ± 5.4 y, weight 76.2 ± 
11.5 kg, height 176.9 ± 8.5 cm). Participants completed 3 standardized whole-body strength 
and power training sessions per week for 5 wk. During the 5-wk training period they were 
assigned to a salmeterol (SAL), formoterol (FOR), or placebo (PLA) group. Participants used 
their inhaler twice per day as instructed and completed assessments of sprint, strength, and 
power at baseline and 1 wk after cessation of the training program. The assessments included 
30-m sprint, vertical jump, 1-repetition-maximum (1RM) bench press, 1RM leg press, peak 
torque flexion and extension, anthropometric evaluation, and Rest-Q questionnaires.  
Results: After 5 wk of strength and power training, 30-m sprint time reduced in FOR (0.29 ± 
0.11 s, P = .049) and SAL (0.35 ± 0.05 s, P = .040) groups compared with PLA (+0.01 ± 0.11 
s). No significant change was found in other assessments of strength, mood, or skinfold 
thickness. 
Conclusions: When strength and power training is combined with the inhalation of FOR or 
SAL over a 5-wk period, moderately trained individuals experience an improvement in 30-m 
sprint performance.  
Key words: performance, asthma, doping  
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Introduction 
The 2019 World Anti-Doping Agency (WADA)1 permits athletes to use inhaled 
therapeutic doses of β2-agonists salbutamol (1600 µg/d, no more than 800 µg in a 12-h period), 
formoterol (54 µg/d), and salmeterol (200 µg/d). However, there is some debate as to whether 
the current rules allow unscrupulous athletes, with and without asthma-related conditions, to 
use inhaled β2-agonists for the purpose of benefitting from a potential ergogenic action.  
Previous research investigating the acute and short term use (e.g. 2 weeks) of inhaled 
β2-agonists suggests they do not have an ergogenic action on endurance performance.2 
Furthermore, endurance performance is not improved from acute doses of inhaled formoterol3 
and salmeterol.4 However, moderately and highly trained individuals may experience enhanced 
strength and power performance from the acute use of short acting 5 and long acting β2-
Agonists.6  
The mechanisms behind the ergogenic action from acute doses that have been observed 
in skeletal muscle include: β2-adrenergic stimulation that counteracts exercise-induced 
reductions in Na+-K+ ATPase maximum rate of activity, elevated glycolytic activity during 
high intensity exercise and enhanced rates of Ca2+ release and uptake from the sarcoplasmic 
reticulum.5 Furthermore, increased anaerobic ATP utilisation has been suggested as a potential 
mechanism.6 However, others have failed to demonstrate changes in peak force velocity, and 
have shown maximal strength deteriorates following acute oral terbutaline administration.7   
Long-term use of β2-Agonists also has the potential to produce an ergogenic action. 
Data from animal models suggests long-term β2-adrenergic stimulation results in muscle 
hypertrophy.8 Studies investigating the long-term β2-adrenergic stimulation in humans suggest 
increases in skeletal muscle mass9 and portioning of amino acids from oxidative loss toward 
protein synthesis 10 may occur. Furthermore, salbutamol has been shown to counteract a 
negative net protein balance following resistance training in males.11 These changes to skeletal 
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muscle from long-term use of β2-Agonists has been shown to increase peak muscle strength12 
and power output, 13 whilst also inducing a slow-to-fast twitch muscle phenotype transition in 
humans.14  
Long-term use of β2-Agonists may also decrease body fat due to increased fat 
mobilization from adipose tissue13, decreased fat synthesis in adipose tissue and liver15 , or a 
combination of both. 16 Although there is clear potential for ergogenic action with oral or supra-
therapeutic inhaled doses of β2-Agonists, we do not know whether long term stimulation of β2-
adrenoreceptors via therapeutic doses of long acting inhaled β2-Agonists has a similar effect.  
Endurance training has been shown to confound the ergogenic action of inhaled short 
acting β2-Agonists17. However the ergogenic action of inhaled short acting β2-Agonists is 
augmented with resistance training. 9 It is not known whether there is a similar interaction when 
long acting β2-Agonists are inhaled whilst engaging in strength training.  This is a realistic 
consideration as athletes using long acting inhaled β2-Agonists (salmeterol or formoterol) are 
prescribed to do so on a daily basis, which may modify their response to strength and power 
training.  
Accordingly, the purpose of this study was to investigate the impact of therapeutic 
doses of inhaled salmeterol or formoterol combined with a resistance exercise training 
programme on 30 m sprint, strength, power, mood, stress and skinfold thickness. 
Methods 
The study procedure was approved by the Faculty of Science Research Ethics 
Committee at the University of Kent and followed the ethical principles for medical research 
involving human subjects set by the World Medical Association Declaration of Helsinki.  
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To ensure none of our participants had asthma or exercise induced bronchospasm (EIB) 
they were required to declare they had no history of asthma diagnosis and objectively 
demonstrate this via a eucapnic voluntary hyperpnoea challenge (EVH).  
Participants completed a series of assessments prior to and following a five week 
resistance exercise training programme, which included: 30 m sprint, peak concentric strength 
of the knee extensors and flexors, maximal one repetition of bench and leg press, vertical jump 
and skinfold thickness. Participants were randomly allocated to one of three treatments to be 
inhaled twice daily: placebo inhaler (PLA), 100 µg inhaled salmeterol (SAL) or 12 µg inhaled 
formoterol (FOR). Over the course of five weeks participants administered their inhaler as 
instructed and completed supervised strength and power training sessions three times per week. 
The training programme included lower body and upper body exercises that progressed 
appropriately over the five weeks. Sprint training focused on quickness and coordination. To 
assess the status of recovery from day to day training the participants completed the Recovery-
Stress questionnaire (figure 1).   
Participants: We initially recruited twenty-four male participants however one male 
participant withdrew from the study due to an injury not related to the study in week four. We 
therefore had twenty-three healthy recreationally active males (mean ± SD: age 27.9 ± 5.5 
years; height 179.8 ± 7.3 cm; weight, 78.8 ± 10.3 kg) and fifteen recreational active females  
(age 24.1 ± 4.1 years; weight 65.4 ± 9.5 kg; height 168 ± 4.3 cm) who volunteered for the 
study, provided informed consent and completed the study.  All participants had been involved 
in strength and power activities over the past year during their weekly training habits. The 
heterogeneous nature of the male participants taking part in the study was characterised by their 
involvement in a variety of sports at an amateur competitive level including: football (n = 9); 
basketball (n = 4); track and field (n = 2); martial arts (n = 3); swimming (n = 1); running (n = 
2); and cycling (n = 3). Female participants were characterised by their involvement in a variety 
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of sports at an amateur competitive level including: basketball (n = 8); football (n = 4); boxing 
(n = 2); running (n = 1). Prior to participation in the study none of the participants competed in 
strength and power lifting sports. Participants engaged in strength and power training sessions 
at least three times per week completing a diary to record their training engagement and 
progress. 
Broncho-provocation Challenge: All participants were free from asthma and EIB, 
which was confirmed by the presentation of a negative EVH challenge.18 The EVH challenge 
consisted of six minutes breathing cold dry air from a compressed gas cylinder at a target 
minute ventilation of 85% of estimated maximal voluntary ventilation (30 x baseline FEV1). 
Maximal flow-volume loops were measured at baseline and 3, 5, 7, 10 and 15 minutes post 
EVH. An EVH challenge was deemed positive if the individuals FEV1 fell >10% from baseline 
FEV1 at two consecutive time points following the EVH challenge.  
Treatment groups: Participants were randomly assigned to one of three groups using 
a minimisation method.19 As part of this randomisation we factored in gender balance between 
groups so that they were balanced eight males to five females in each group. In a single blinded 
randomised design each group was allocated to use either: 
 Placebo inhaler (containing water vapor) twice daily (PLA) 
 Inhaled 100 µg salmeterol twice daily (Serevant, Accuhaler 50 µg/dose, GSK, UK) 
 Inhaled 12 µg formoterol twice daily (Oxis Turbohaler 6 µg/dose, Astra Zeneka, UK)  
These doses were chosen as they are high therapeutic doses permitted for use by 
athletes.1 Participants were instructed about their inhaler technique. At each training session 
researchers checked the participants were using their inhalers as instructed by reading the 
inhalation counter on their device to confirm they were adhering to the protocol.   
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Assessments 
Participants completed each of the following assessments at baseline and one week after 
the final inhaler dose and training session (figure 1). Prior to the start of the study participants 
attended two familiarisation sessions for all assessments.  
30 meters sprint: Participants were asked to complete a maximal 30 m sprint on a non-
motorised calibrated treadmill (Force Treadmill System, Woodway, SA). The peak speed data 
collected from the non-motorised treadmill has been described in literature to be approximately 
80% of that achieved in free-sprint track performance.20 Each participant completed three 30 
m sprints separated by 5 minutes. The fastest 30 m sprint was recorded. 
Isokinetic dynamometry: Participants performed three maximal voluntary 
contractions of the knee extensors at 120o.s-1 and three maximal voluntary contractions of the 
knee flexors at 120o.s-1 (Biodex 830-210, Biodex Medical System, Shirley, New York, USA). 
The highest peak torque measurement was taken as a measurement of maximal strength in the 
knee extensors and knee flexors. 
Maximal One Repetition Bench Press and incline Leg Press: Participants 
progressively worked toward a maximum one repetition for both incline leg press and bench 
press. The incline leg press (CF800 Leg Press/Hack Squat Machine, Bodymax, UK) was 
performed at 45o by first completing a six repetitions maximum. This was followed by a four 
repetition maximum and a two repetition maximum at increasing weights. The bench press was 
performed using a 20 Kg Olympic bar with weights added to it accordingly. The participants 
continued to complete one-repetition efforts at increasing weight until they reached failure. 
Each effort was separated by four minutes.21 The weight lifted during the last complete 
repetition was taken as their maximal one repetition.22  
Power – Counter movement vertical jump (CMJ): A counter movement jump was 
performed on a jump mat (Probiotics Inc., Huntsville, AL, USA). The participants were 
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instructed to jump as high as they could by performing a CMJ with an arm swing. Coaching of 
technique was only provided if participants consistently landed off the jump mat demonstrating 
poor technique. Participants performed three counter movement jumps and the greatest vertical 
jump height achieved was recorded. 
Body Composition: Skin-fold thickness was taken at the following recognised sites on 
the right hand side of the body: triceps, biceps, subscapular and supraspinale. All measurements 
were taken by the same technician using a single set of Harpenden skinfold callipers (Baty 
International, Sussex, UK). Skin-fold thickness measurements were taken from each site 
consecutively a total of two times with the mean of the two measurements taken as the skin 
fold thickness for each specific site. The criterion for a valid measurement was a difference of 
less than 1 mm between the two totals.  If this was not the case the measurements were repeated 
until the criterion was met. The sum of four mean skin-folds thickness measurement was 
calculated.  
Recovery, Sleep and Mood Questionnaires: Participants completed questionnaires in 
week three and five to measure recovery and stress from training and mood. Recovery and 
stress from training were assessed via the Recovery-Stress Questionnaire for athletes.23 Mood 
was assessed using the Brunel Mood Scale.24  
Strength and Power Training Programme: Following the completion of the above 
baseline assessments participants began a strength and power training programme. The training 
programme focused on developing strength, power and sprinting. Participants training was 
individualised and supervised by a strength and conditioning specialist. 
Participants training incorporated lower body exercise such as lunges, squat, leg press 
and leg curl; upper body exercises included chest and shoulder press, shoulder dumbbell raise 
and arm exercises using both barbell and dumbbells. Each training session consisted of twelve 
exercises. Each exercise was completed with a target of completing three sets of eight 
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repetitions, with each set separated by two minutes. When participants were able to complete 
all three sets they increased the load. Sprint training included exercises involving quickness 
and coordination with a set of 5 to 10 m sprint accelerations performed five times at the end of 
the training session. Participants recorded total work done during each session. Participants 
were asked not to engage in strength, power or sprint training outside of the programme. 
Aerobic training outside of the study was restricted to two sessions per week. It was not feasible 
to accurately record or control for the intensity and duration of any additional endurance based 
training.  
Statistical Analysis: Changes in sprint performance, strength, power, mood, recovery, 
sleep and skinfold thickness from baseline to week five between PLA, SAL and FOR were 
analysed using a mixed model repeated measures ANOVA (3 group x 2 time). Assumptions 
for this analysis was checked and corrected for according to the methods described by Atkinson 
and Nevill.25 A P<0.05 was deemed significant. Effect size was calculated according to 
Cohen’s statistical power analysis used to indicate the standardised difference between two 
means measuring small, medium and large effect sizes (d= 0.20, 0.50, 0.80.).26  
Results 
There were no differences at baseline between groups for any of the sprint (p=0.670), 
strength and power (p=0.226), anthropometric (p=0.438) and skinfolds (p=0.762). 
Psychological variables were different at baseline (p=0.001) but not at week 3 and week 5 
between groups (p=0.234) (table 1, 2 and 3). 
30 m Sprint 
Between baseline and week five 30 m sprint time improved in both the FOR (–0.29 ± 
0.11 s; p=0.049; ES= 0.50) and SAL (–0.35 ± 0.05 s; p=0.040; ES= 0.41) groups when 
compared to the placebo group (+0.01 ± 0.11 s; see table 1 and figure 2).  
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Strength and Power Assessments 
Over the five weeks all groups improved markers of strength and power (see table 1). 
There was no difference in the rate of improvement between groups.  
Anthropometric measures 
Over the five weeks of training the sum of skinfold thickness across four sites did not 
change significantly (p=0.762; table 2). No significant changes in body mass between groups 
were observed over the five weeks of training (p=0.915; table 2). 
Recovery, Sleep and Mood Questionnaires 
Recovery-Stress Questionnaire index did not change (p=0.395) across the five week 
training period in PLA, SAL or FOR groups (table 3).  
Discussion 
Our study suggests that 30 m sprint performance is improved when daily doses of 
inhaled formoterol or salmeterol are combined with strength, power and sprint training over a 
five week period. However we did not observe significant changes in strength, power, mood, 
recovery or skinfold thickness between formoterol, salmeterol and placebo over the five-week 
period. 
The improved 30 m sprint performance following five weeks of inhaled formoterol or 
salmeterol administration in our study was similar to previous reports examining acute and 
long term use of β2-Agonists. Likewise, administration of oral β2-Agonists enhances muscle 
strength and peak power output during maximal cycling. 27, 28, 29 Improvements in sprint and 
power performance from short-term use of β2-Agonists has been suggested to be as a result of 
increased skeletal muscle mass and maximal muscle force production, leading to greater initial 
peak power.13 Furthermore, high doses of formoterol can augment resting energy expenditure 
and fat utilization in active males.10 However, in some cases where authors report changes in 
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peak power this does not correspond to significant improvements in the mean power produced 
during a wingate test.12 Although wingate performance is related to sprint performance, the 
duration of our 30 m sprint was approximately seven seconds compared to the 30 s Wingate 
challenge. It may be long-term use of formoterol and salmeterol have a greater potential for 
ergogenic action for explosive sprints lasting under 10 s, compared to longer sprinting 
activities. Further research is required to confirm this hypothesis.    
In our study although we observed an improvement in sprint performance we did not 
see changes in strength, power or skinfold thickness. This may due to the smaller therapeutic 
doses of salmeterol and formoterol use in our study, compared to other studies using supra-
therapeutic doses. 30 Although, our method of using skin fold thickness to measure changes in 
body composition may not have been sensitive enough to detect changes in muscle mass. By 
using other means of measuring changes in body composition (e.g. DEXA) we may have 
detected changes in muscle mass. In a recent study by Jessen et.al 9 they observed a significant 
increase in lean body mass of 1.03 – 1.04 kg as detected by DEXA following daily inhalation 
of 4 mg terbutaline over a four week period whilst participants engaged in strength training and 
also those in an habitual life-style group, but this was not the case for those engaging in 
endurance training.  
Gender differences in pulmonary anatomy may influence the potential ergogenic action 
of formoterol and salmeterol. Although previous studies that have suggested this may be the 
case for salbutamol, the hypothesis has not been rigorously investigated.31 Due to the relatively 
small number of females in our study, our data was underpowered to conduct meaningful sub 
analyses. 
Future studies should investigate the relationship between long acting β2-Agonists 
administration in male and female athletes and the bio-availability required to stimulate an 
increase in muscle protein turnover and synthesis between sexes. Previous studies suggest 
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formoterol induces opposing effects between oxidation and synthesis but ultimately results in 
net anabolic gain because of a greater anti-catabolic effect (oxidation) over reduced synthesis.10 
In females, these anti-catabolic and synthesis effects were three-fold larger when compared to 
men.10 
A limitation of this study is that we cannot assume the observations we have seen in 
our participants who take part in recreational sport translate to elite athletes. However, if elite 
athletes did take part in our study they may have been subject to a doping test, in which they 
may have provided a urine sample with a concentration of formoterol that is above the 
permitted level and therefore committed an anti-doping violation. For this reason we excluded 
elite athletes from participating. Future studies may incorporate highly trained individuals to 
investigate whether they experience a similar response to sprint performance following five 
weeks of inhaling either formoterol or salmeterol. 
Previous studies have demonstrated that the potential ergogenic action of long-term use 
of β2-Agonists can be confounded by endurance training.9 In our study we specifically focused 
on strength and power training which has previously been shown not to confound increases in 
lean mass. We have not investigated whether endurance training would confound the 
improvements in 30 m sprint performance, which has been previously reported when short 
acting β2-Agonists have been used over a four to six week period incorporating endurance 
training.32  
Athletes use formoterol and salmeterol to protect against bronchoconstriction. Both 
drugs have side effects including: increased heart rate, headaches, tremors, muscle cramps and 
palpitations. It is not known whether athletes using either inhaled formoterol or salmeterol 
increase the risk of these side effects. However, in our study we did not observe athletes 
reporting these symptoms throughout the study. Furthermore, we did not see any significant 
differences between the recovery, sleep and mood between groups. We investigated these 
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parameters to see if salmeterol or formoterol may have influenced perception of recovery 
between training days. As we have not detected any differences between groups we can exclude 
this as a potential mechanism to explain improvements in 30 m sprint performance. 
Conclusion 
This study was the first to demonstrate five weeks of therapeutic doses of either inhaled 
salmeterol or formoterol in combination with strength, power and sprint training may improve 
30 m sprint performance. At this stage we are not able to conclude that similar effects will 
occur in highly trained athletes using similar doses. Therefore anti-doping stake-holders may 
wish to commission investigations into whether highly trained athletes experience a similar 
ergogenic action from inhaled formoterol or salmeterol. These studies should be conducted 
before changes to the WADA Prohibited List are recommended. However, our findings suggest 
that consideration should be given to closer monitoring of inhaled long acting β2-Agonists use 
by athletes in and out of competition. Future research is required to investigate the mechanism 
behind the potential improvement in sprint performance in both males and females.  
Practical Application 
Our results demonstrate long-term use of long acting beta-2-agonists may lead to 
improvements in sprint performance. Before changes are made to the WADA anti-doping code, 
similar research project on highly trained athletes should be conducted. 
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Figure 1: Schematic representation of the study across five week training intervention 
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Figure 2: 30 m sprint performance at pre and post five weeks training for  (a) participants in 
PLA, (b) participants in SAL, (c) participants in FOR and (d) mean 30 m sprint performance 
in PLA, SAL and FOR groups.   
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Table 1: 30 meters Sprint, Power and Strength Performance in SAL, FOR and PLA groups at 
week 0 and week 5 (Mean ± SD) 
 
 SAL FOR PLA 
 
Week 
0 
Week 
5 
Mean 
Change 
Week 
0 
Week 
5 
Mean 
Change 
Week 
0 
Week 
5 
Mean 
change 
1RM Inc. Leg 
Press (Kg) 
102 ± 
59 
135 ± 
92 
33 ± 41 
111 ± 
59 
135 ± 
92 
24 ± 44 
102 ± 
58 
131 ± 
83 
29 ± 41 
1RM Hack Squat 
(Kg) 
135 ± 
57 
201 ± 
57 
66 ± 40 
123 ± 
33 
190 ± 
34 
67 ± 15 
108 ± 
34 
166 ± 
52 
58 ± 21 
1RM Bench Press 
(Kg) 
55 ± 
20 
64 ± 
27 
9 ± 26 
51 ± 
20 
57 ± 
17 
6 ± 18 
53 ± 
27 
60 ± 
31 
7 ± 44 
Leg Extension 
(N•m) 
226 ± 
48 
228 ± 
22 
1 ± 41 
199 ± 
24 
212 ± 
23 
13 ± 33 
186 ± 
19 
189 ± 
36 
3 ± 27 
Leg Flexion 
(N•m) 
123 ± 
23 
137 ± 
10 
14 ± 25 
121 ± 
18 
128 ± 
16 
7 ± 9 
110 ± 
12 
121 ± 
10 
11 ± 14 
Vertical Jump 
(cm) 
49.6 ± 
10.7 
53.5 ± 
9.4 
3.9 ± 5.2 
49.7 ± 
8.8 
54 ± 
10.4 
4.3 ± 5.9 
49.4 ± 
8.1 
52.3 ± 
8.4 
2.9 ± 
7.3 
30 m Sprint (s) 
7.38 ± 
0.70 
7.03 ± 
0.72* 
- 0.35 ± 
0.05 
7.10 ± 
0.70 
6.81 ± 
0.74* 
- 0.29 ± 
0.11 
7.40 ± 
1.33 
7.41 ± 
1.23 
0.01 ± 
0.11 
Abbreviations: 1RM = one maximal repetition; SAL = salmeterol; FOR = formeterol; PLA = placebo 
* = Significantly different from PLA (P < 0.05). 
Incline Leg press 45°, Hack Squat and Bench Press measured is reported at 1RM; Leg Extension, Leg Flexion is 
reported as  
Peak Torque measured at 120o.s- 
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Table 2: Skinfolds and Body Mass from week 0 to week 5 in SAL, FOR and PLA groups. 
Mean ± SD. 
 
 SAL FOR PLA 
 
Week 
0 
Week 
5 
Mean 
Change 
Week 
0 
Week 
5 
Mean 
Change 
Week 
0 
Week 
5 
Mean 
change 
Skinfolds 
4 (mm) 
46 ± 
18 
41 ± 
12 
- 5 ± 17 
47 ± 
16 
46 ± 
15 
-1 ± 28 
44 ± 
10 
42 ± 7 - 2 ± 12 
Body Mass 
(Kg) 
80.8 ± 
12 
81.6 ± 
10.6 
- 0.8 ± 
2.1 
76.6 ± 
7.1 
76.9 ± 
5.8 
0.3 ± 4.1 
80.4 ± 
13.3 
80.1 ± 
13.5 
- 0.3 ± 
7.4 
Abbreviations: 4 = Sum of the four skinfold sites (triceps, biceps, subscapular and supraspinale); RM 
= repetition maximum; SAL = salmeterol; FOR = formoterol; PLA = placebo 
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Table 3: Rest Q Recovery and Stress Index values in weeks 3 and 5 in SAL, FOR and PLA 
groups (Mean ± SD).  
 
 SAL FOR PLA 
 
Week 
3 
Week 
5 
Mean 
Change 
Week 
3 
Week 
5 
Mean 
Change 
Week 
3 
Week 
5 
Mean 
change 
Rest Q Recovery 
Index (A.U.) 
2.5 ± 
0.1 
2.7 ± 
0.4 
0.2 ± 0.5 
2.4 ± 
0.2 
2.5 ± 
0.4 
 0.1 ± 
0.5 
2.6 ± 
0.3 
2.8 ± 
0.1 
- 0.2 ± 
0.1 
Rest Q Stress Index 
(A.U.) 
1.9 ± 
0.1 
1.8 ± 
0.2 
- 0.1 ± 
0.7 
1.7 ± 
0.1 
1.8 ± 
0.2 
0.1 ± 0.7 
1.9 ± 
0.1 
1.8 ± 
0.2 
- 0.1 ± 
0.4 
Abbreviations: A.U. = arbitral units; SAL = salmeterol; FOR = formeterol; PLA = placebo 
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